TOKYO, Mar 17 (Pulse News Wire) – Cellsource CO.,LTD. (4880.T) announced today that it received approval from the Tokyo Stock Exchange for its market classification change application.
As a result, the company will transition to the Standard Market effective March 24, 2026. Additionally, due to the recent approval, the company has withdrawn its previously disclosed plan related to meeting the maintenance standards of the Prime Market as of October 31, 2025. The previous plan was initiated on January 28, 2026, addressing non-compliance with the circulating share market capitalization requirement.
Following the move to the Standard Market, CellSource remains committed to advancing regenerative medicine. The company plans to enhance profitability while maintaining governance and liquidity, aligning long-term business growth with increased enterprise value. CFO Satoshi Iga stated, “We appreciate our shareholders' continued support and guidance.” --- Cellsource CO.,LTD.
(4880.T) will continue its efforts toward realizing regenerative medicine solutions within the structured environment of the Standard Market, aiming to strengthen its revenue base and deliver sustainable growth.
🟢 Confidence: High AI-translated content.